欧洲企业在中国丨升级在华技术中心，中国生物医药创新“圈粉”这家法企

Group 1 - The rapid development of China's biopharmaceutical sector has attracted significant foreign investment, with Gattefossé celebrating 20 years in the Chinese market and expanding its technical center in Shanghai by over 60% [1] - Gattefossé's CEO highlighted that Asia accounts for nearly 25% of the group's revenue, with China playing a crucial role in this growth [1] - Over the past two decades, China has transformed from a follower to a leader in the pharmaceutical and personal care sectors, driving continuous innovation [1] Group 2 - Gattefossé's China General Manager noted that nearly 30% of new drug molecules originate from Chinese research, reflecting the country's strategic shift towards original small molecules, peptides, and biopharmaceuticals [2] - The company has observed significant global recognition of leading CDMOs and emerging biotech firms in China, which have attracted billions in venture capital [2] - Gattefossé is committed to deepening collaborations with local partners and universities, recognizing the immense potential in the Chinese market [2] Group 3 - The company aims to keep pace with China's rapid innovation and respond to local customer needs, viewing the future in China with optimism [2] - Gattefossé plans to increase investments, strengthen local teams, and create new job opportunities in China, demonstrating a long-term commitment to the market [2]